Replies to post #179581 on Biotech Values

[Bickema]

If this is the case then ENTA needs to start researching and developing new drugs soon.

[DewDiligence]

ENTA—The problem is that there is nobody else but abbvie. My thesis is that it is too hard for a 3rd party (beyond abbvie) to come in and untangle the legalities.

Respectfully disagree. I don’t think there are any legal impediments to having NVS—or another company other than ABBV—pursue buyout interest in ENTA.